Athira Pharma Files Q1 2025 10-Q
Ticker: LONA · Form: 10-Q · Filed: May 9, 2025 · CIK: 1620463
| Field | Detail |
|---|---|
| Company | Athira Pharma, INC. (LONA) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Athira Pharma's Q1 2025 10-Q is in, showing financial status and stock details.
AI Summary
Athira Pharma, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational highlights, including details on its common stock and retained earnings as of March 31, 2025. The filing also references its Bothell, Washington facilities and its participation in the Two Thousand And Twenty Four Inducement Equity Incentive Plan.
Why It Matters
This filing provides investors with a snapshot of Athira Pharma's financial health and operational status for the first quarter of 2025, crucial for understanding its ongoing development and investment potential.
Risk Assessment
Risk Level: medium — As a biotechnology company, Athira Pharma operates in a high-risk, high-reward sector with significant regulatory and clinical trial uncertainties.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the financial snapshot date)
- 2024-03-31 — Prior Year Quarter End Date (For comparative financial analysis)
Key Players & Entities
- Athira Pharma, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- Bothell, Washington (location) — Company's business address
- Two Thousand And Twenty Four Inducement Equity Incentive Plan (plan) — Mentioned in the filing
FAQ
What is the total number of shares available for future grant under the Two Thousand And Twenty Four Inducement Equity Incentive Plan as of March 31, 2025?
The filing indicates 'SharesAvailableForFutureGrantUnderTwoThousandTwentyFourInducementEquityIncentivePlanMember' as of 2025-03-31, but the specific number is not provided in the excerpt.
What were Athira Pharma's retained earnings as of March 31, 2025?
The filing references 'us-gaap:RetainedEarningsMember' for 2025-03-31, but the specific dollar amount is not detailed in this excerpt.
What is the company's primary business classification?
Athira Pharma, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
When was the company formerly known as M3 Biotechnology, Inc.?
The date of the name change from M3 Biotechnology, Inc. to Athira Pharma, Inc. was 20140924.
What is the filing date of this 10-Q report?
The 10-Q report was filed on 20250509.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Athira Pharma, Inc. (LONA).